



Universiteit
Leiden
The Netherlands

Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis

Peters, R.; Yasar, S.; Anderson, C.S.; Andrews, S.; Antikainen, R.; Arima, H.; ... ; Anstey, K.J.

Citation

Peters, R., Yasar, S., Anderson, C. S., Andrews, S., Antikainen, R., Arima, H., ... Anstey, K. J. (2020). Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. *Neurology*, 94(3), E267-E281. doi:10.1212/WNL.00000000000008732

Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3185217>

Note: To cite this publication please use the final published version (if applicable).

Investigation of antihypertensive class, dementia, and cognitive decline

A meta-analysis

Ruth Peters, PhD, Sevil Yasar, PhD, Craig S. Anderson, PhD, Shea Andrews, PhD, Riitta Antikainen, PhD, Hisatomi Arima, PhD, Nigel Beckett, MD, Joanne C. Beer, PhD, Anne Suzanne Bertens, MD, Andrew Booth, PhD, Martin van Boxtel, PhD, Carol Brayne, MD, Henry Brodaty, DSc, Michelle C. Carlson, PhD, John Chalmers, PhD, Maria Corrada, ScD, Steven DeKosky, MD, Carol Derby, PhD, Roger A. Dixon, PhD, Françoise Forette, MD, Mary Ganguli, MD, Willem A. van Gool, PhD, Antonio Guaita, MD, Ann M. Hever, PhD, David B. Hogan, MD, Carol Jagger, PhD, Mindy Katz, MPH, Claudia Kawas, MD, Patrick G. Kehoe, PhD, Sirkka Keinänen-Kiukkaanniemi, PhD, Rose Ann Kenny, MD, Sebastian Köhler, PhD, Setor K. Kunutsor, PhD, Jari Laukkanen, PhD, Colleen Maxwell, PhD, G. Peggy McFall, PhD, Tessa van Middelaar, MD, Eric P. Moll van Charante, PhD, Tze-Pin Ng, MD, Jean Peters, PhD, Iris Rawtaer, MMed, Edo Richard, PhD, Kenneth Rockwood, MD, Lina Rydén, MD, Perminder S. Sachdev, MD, Ingmar Skoog, PhD, Johan Skoog, MSc, Jan A. Staessen, PhD, Blossom C.M. Stephan, PhD, Sylvain Sebert, PhD, Lutgarde Thijs, MSc, Stella Trompet, PhD, Phillip J. Tully, PhD, Christophe Tzourio, PhD, Roberta Vaccaro, MSc, Eeva Vaaramo, MSc, Erin Walsh, PhD, Jane Warwick, PhD, and Kaarin J. Anstey, PhD

Correspondence

Dr. Peters
r.peters@imperial.ac.uk

Neurology® 2020;94:e267-e281. doi:10.1212/WNL.00000000000008732

Abstract

Objective

High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimizing cognition. Our objective was to determine whether any particular antihypertensive class was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original participant data.

Methods

To identify suitable studies, MEDLINE, Embase, and PsycINFO and preexisting study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data sharing and collaboration. Outcome measures were incident dementia or incident cognitive decline (classified using the reliable change index method). Data were separated into mid and late-life (>65 years) and each antihypertensive class was compared to no treatment and to treatment with other antihypertensives. Meta-analysis was used to synthesize data.

Results

Over 50,000 participants from 27 studies were included. Among those aged >65 years, with the exception of diuretics, we found no relationship by class with incident cognitive decline or dementia. Diuretic use was suggestive of benefit in some analyses but results were not consistent across follow-up time, comparator group, and outcome. Limited data precluded meaningful analyses in those ≤65 years of age.

Conclusion

Our findings, drawn from the current evidence base, support clinical freedom in the selection of antihypertensive regimens to achieve blood pressure goals.

Clinical trials registration

The review was registered with the international prospective register of systematic reviews (PROSPERO), registration number CRD42016045454.

From Neuroscience Research Australia (R.P., K.J.A.); University of New South Wales (R.P., C.A., H.B., J.C., P.S.S., K.J.A.), Sydney, Australia; Johns Hopkins University (S.Y., M.C.C.), Baltimore, MD; The George Institute for Global Health (C.A., J.C.), Sydney, Australia; The George Institute China at Peking University Health Sciences Center (C.A.), Beijing, China; Icahn School of Medicine at Mount Sinai (S.A.), New York, NY; Center for Life Course Health Research/Geriatrics (R.A., S.K.-K., S.S., E.V.), University of Oulu; Medical Research Center Oulu (R.A.), Oulu University Hospital; Oulu City Hospital (R.A.), Finland; Department of Preventive Medicine and Public Health (H.A.), Fukuoka University, Japan; Guys and St Thomas' NHS Foundation Trust (N.B.), London, UK; University of Pittsburgh (J.C.B., M.G.), PA; Leiden University Medical Centre (A.S.B., S.T.), the Netherlands; University of Sheffield (A.B., J.P.), UK; School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology (M.v.B., S.K.), Maastricht University, the Netherlands; University of Cambridge (C.B.), UK; University of California (M.C., C.K.), Irvine; University of Florida (S.D.), Gainesville; Albert Einstein College of Medicine (C.D., M.K.), New York, NY; University of Alberta (R.A.D., G.P.M.), Edmonton, Canada; International Longevity Centre (F.F.), Paris, France; University of Amsterdam (W.A.v.G., E.P.M.v.C.), the Netherlands; Golgi Cenci Foundation (A.G., R.V.), Milan, Italy; Trinity College Dublin (A.H., R.A.K.), Ireland; University of Calgary (D.B.H.), Canada; Newcastle University (C.J., B.C.M.S.), Newcastle upon Tyne; University of Bristol (P.G.K., S.K.K.), UK; University of Eastern Finland (J.L.), Kuopio; Faculty of Sport and Health Sciences, University of Jyväskylä (J.L.), Finland; School of Pharmacy, University of Waterloo (C.M.), Ontario, Canada; Academic Medical Center (T.v.M., E.R.), Amsterdam; Donders Institute for Brain, Cognition and Behaviour (T.v.M., E.R.), Radboud University Medical Center, Nijmegen, the Netherlands; National University of Singapore (T.-P.N.); Sengkang General Hospital (I.R.), Singhealth Duke-NUS Academic Medical Centre, Singapore; Dalhousie University (K.R.), Halifax, Canada; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy (L.R., I.S.), and Department of Psychology (J.S.), Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Sweden; University of Leuven (J.A.S., L.T.), Belgium; Bordeaux Population Health Research Center (P.J.T., C.T.), UMR 1219, CHU Bordeaux, University of Bordeaux, Inserm, France; University of Adelaide (P.J.T.); Australian National University (E.W.), Canberra, Australia; and University of Warwick (J.W.), Coventry, UK.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

MORE ONLINE

▶ CME Course

[NPub.org/cmelist](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000000/)

Glossary

ACE-I = angiotensin-converting enzyme inhibitors; **AHM** = antihypertensive medication; **ARB** = angiotensin receptor blockers; **BB** = β -blockers; **BP** = blood pressure; **CCB** = calcium channel blockers; **CI** = confidence interval; **DSM-III-R** = *Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised*; **DSM-IV** = *Diagnostic and Statistical Manual of Mental Disorders, 4th edition*; **MMSE** = Mini-Mental State Examination; **OR** = odds ratio; **RCI** = reliable change index; **RCT** = randomized controlled trial; **SBP** = systolic blood pressure.

Dementia is a major public health problem affecting around 50 million individuals worldwide. A new case is diagnosed every 3 seconds and prevalence is estimated to rise to 131.5 million cases by 2050.¹ High blood pressure (BP) is widely recognized as one of the main modifiable risk factors for dementia.^{2–5} Even though BP-lowering treatment is readily available, we lack clinical hypertension guidelines for the management of brain health. This reflects in part the conflicting evidence on the best antihypertensive class for optimizing cognitive outcomes and reducing risk of dementia, with some classes, e.g., calcium channel blockers, thought to have a pleiotropic neuroprotective effect beyond BP-lowering.^{3,4,6–14} Existing meta-analyses are limited because information is lost with pooling of published results that conflate data across different age groups (mid and late-life); lack data on minimum length of exposure to antihypertensive class; adjust for differing confounders; use differing statistical measures, variable definitions of cognitive outcomes, and varied lengths of follow-up; and combine treated and untreated comparator groups.^{11–14} We have conducted a two-stage individual participant data meta-analysis examining antihypertensive class using standardized measures across studies and subsequent meta-analysis. Data from 56,866 participants drawn from 27 studies were synthesized to evaluate the relationship between each antihypertensive class and incident cognitive decline and dementia.

Methods

Data sources and searches

To identify studies for inclusion in this systematic review and meta-analysis, the databases MEDLINE, MEDLINE In-Process, Embase, and PsycINFO were searched from inception to December 2017. The search terms used were (dementia or cognit* or mild cognitive impairment or Alzheimer disease or dementia vascular or dementia multi-infarct) and (antihypertensives or antihypertensive agents or diuretic or diuretics or thiazide or thiazide-like or calcium channel blocker or calcium channel blockers or calcium antagonist or angiotensin-converting enzyme inhibitor or angiotensin-converting enzyme inhibitors or ACE inhibitors or angiotensin receptor blocker or angiotensin receptor blockers or ARB or β -blocker or adrenergic β -antagonist). Details of the search strategy are given in appendix e-A (doi.org/10.5061/dryad.t9n4n3p). Reference lists and lists of studies contained within established study consortia relating to cognitive outcomes were screened for potentially relevant published articles and studies.

Experts in the field were also consulted and searches were carried out for relevant trials using the following sources:

- Cochrane database from 1980 to date of search
- ISRCTN Register (international registry of trials and studies)
- ClinicalTrials.gov

The lead reviewer (R.P.) carried out the literature searches. All identified abstracts, or titles where abstracts were unavailable, were double-read and a list of potentially relevant evidence compiled independently by each of the 2 reviewers (R.P., J.P.). The lists were compared with differences resolved by discussion. Once the list of possible publications was agreed upon, full texts of relevant documents were independently read and assessed for relevance. To minimize the effect of publication bias, a list of potentially eligible studies was also compiled by examining those included in preexisting consortia, i.e., collaborative groups of longitudinal studies with a focus on cognitive outcomes. Publications, protocols, and web information were searched for each of the studies in the consortia to identify whether they might have suitable data for inclusion. The lead or corresponding author from each publication/study was then contacted and asked to provide raw data or aggregate data summaries, using a standard template, for use in a study-level meta-analysis.

Study selection

Inclusion criteria

- Prospective longitudinal studies or trials of antihypertensives with data on antihypertensive class, a comparator group, and with a mean follow-up ≥ 1 year
- Objective assessment of cognitive function on at least 2 occasions or assessment of dementia as an outcome using standard diagnostic or research criteria
- Human studies

Exclusion criteria

- Non-English publications (in the absence of resources for translation)
- Studies solely using medical record databases
- Studies in populations with cognitive impairment

Data extraction, harmonization, and reduction in risk of bias

Exposure to an antihypertensive medication (AHM) class was present if recorded over a minimum of a 12-month period, based on individual study records of antihypertensive drug use.

AHM classes were defined as calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors (ACE-I), diuretics, β -blockers (BB), and angiotensin receptor blockers (ARB).

Participants with a diagnosis of dementia or cognitive impairment at baseline were excluded. Incident cognitive decline was assessed using the reliable change index (RCI) using the Chelunes method.¹⁵ Since the cognitive data are drawn from different populations and with some variation in repeat testing times, this method allows standardization of reliable decline across cognitive tests with a fall in the RCI value greater than 1.645, i.e., changes exceeding the 90% confidence interval (CI) for RCI categorized as reliable. Follow-up cognitive testing was required to be after the minimum 1 year AHM exposure period and cognitive change was assessed subsequent to or concurrent with this. Cognitive tests were categorized as screening tests and tests of memory, executive function, attention, and speed of processing. Incident dementia was classified as present or absent. Dementia type was not considered because of the high likelihood of mixed pathology.

As the relationship between BP and cognitive function may differ in mid and late life,³⁻⁵ data were dichotomized by age into (late-life) >65 years at baseline vs (midlife) \leq 65 years. To reduce risk of bias from short follow-up, lag periods of 1 and 5 years were used such that data were separated into those with follow-up durations of \geq 1 or \geq 5 years. The requirement for a minimum follow-up period reduces the risk of inadvertently including prevalent cases. Where study visit frequency meant that all participants had \geq 5 years follow-up, i.e., participants were only seen at intervals of 5 or more years, these were included in the latter category. The analyses for each study dataset followed the same procedure.

Data synthesis and analyses

Meta-analyses were conducted for the endpoints of both cognitive decline and dementia.

Each antihypertensive class was examined separately;

- Compared to no AHM or placebo
- Compared to other AHMs (cohort studies)

In addition, those taking any AHM (all classes) were

- Compared to no treatment (cohort studies)
- Compared to placebo (clinical trials)

Because cognitive change is insidious, classification of event dates is problematic for cognitive outcomes. To reduce bias associated with different study designs and varied duration between cognitive assessments, logistic regression models were used with incident cognitive decline or dementia as the dependent variable. Since the effect of AHM class on cognitive function is thought to be pleiotropic, models examining class were adjusted at study level for baseline systolic

BP or, where this was unavailable, for the presence of hypertension at baseline, plus age, sex, and education. Adjusted results were combined to produce a pooled odds ratio (OR). Raw data relating to the number of cases and controls for each class were also combined to produce an unadjusted pooled ratio. Forest plots were used to show study level and pooled ratios.

To evaluate bias due to participant loss by AHM class, the effect of baseline AHM class on later mortality or dropout was also examined using logistic regression. These analyses were adjusted for baseline systolic BP or presence of hypertension, age, sex, and education.

Random effects models were used for meta-analyses, regardless of heterogeneity measured by I^2 , since the studies were drawn from a range of populations. Where only one study was available for a particular analysis, no meta-analysis could be carried out and results were not reported. The I^2 statistic and Egger test were used to examine heterogeneity and publication bias, respectively.

Finally, to broadly examine the role of study-level characteristics, study OR for the comparison between AHM and no treatment or placebo were plotted against the primary decade of recruitment and percentage of participants who were female, and additional multilevel regression models were run with study OR as the dependent variable. In addition, because of potential differences in the relationship between hypertension and cognitive outcomes by sex, analyses comparing AHM to no treatment or placebo were rerun separately for male and female participants.

Standard protocol approvals, registrations, and patient consents

The review was registered with the international prospective register of systematic reviews (PROSPERO), registration number CRD42016045454. Ethical approval was obtained from the Science and Medical Human Research Medical Committee (DERC). Australian National University approval (reference 2016/500) was granted September 23, 2016. Analyses were carried out using SAS v9.3 and StatsDirect v3.0.198.

Data availability

Data availability depends on agreement from each of the participating studies subject to their regulatory requirements and appropriate data sharing arrangements.

Results

Study characteristics

A pool of 2,429 abstracts was screened and 82 articles were examined at the full-text stage. Of these, articles reporting on 27 studies were retained. Thirty-seven additional potential studies were identified from consortia and expert recommendation (figure e-1, doi.org/10.5061/dryad.t9n4n3p). Of the 64

studies, 5 held no relevant data or indicated that data were no longer maintained¹⁶⁻²⁰; 27 studies^{7-9,21-46} contributed data (table e-1, doi.org/10.5061/dryad.t9n4n3p); and 28 studies did not participate. Reasons for nonparticipation included a lack of valid email contact or no response to inquiries and 4 declined to provide data. There were no evident differences in study design, proportion of study type, population, or region of recruitment between the studies that agreed and those that did not participate. Of those where data were unavailable, 20 were observational studies, 8 were trials, and populations were from Europe, America, Asia, and Australia.

Of the 27 that agreed, 21 were observational cohort studies (14 population-based and 7 selected cohorts), 6 were trials; 2^{22,36} were clinical trials treated as cohort studies (where the randomized intervention was not an antihypertensive agent and where randomized groups had no significant effect on cognitive outcomes) and 4^{7-9,39} were randomized controlled trials (RCTs) of antihypertensive treatment. Studies represented populations from Europe,^{7,8,24,27,28,31-38,40-45} America,^{21-23,26,29,39,42} Australia,^{25,30,43} and Asia.^{8,9,46} In total, there were 43,049 participants from cohort studies and 13,817 from clinical trials with ≥ 1 year follow-up and without prevalent dementia at baseline (table e-1, doi.org/10.5061/dryad.t9n4n3p). Mean baseline age in the sampled studies ranged from 57.0 (SD ± 5.2)²⁴ to 93.0 (SD ± 2.6)²⁶ years with the mean age of participants in the majority of participating studies^{7,21-23,26,27,29,31,33,37,39-43} in the range 70 to 79 years. Mean baseline systolic BP (SBP) was in the normotensive range (≤ 140 mm Hg) for 8 studies,^{21-26,44-46} between 140 and 159 mm Hg for 13 studies,^{8,27-38,43} and ≥ 160 mm Hg for 3 studies.^{7,9,39} For 3 studies,⁴⁰⁻⁴² baseline BP was not available. Twenty-four studies^{7-9,21-23,25-31,33-45} contributed data on those aged >65 years at baseline, and 9^{7,8,24,25,28,32,39,44-46}

had some data on those aged ≤ 65 years at baseline. Twenty-four studies^{7-9,21-31,33-38,40,41,43-46} reported results for cognitive decline from the most commonly used screening test, the Mini-Mental State Examination (MMSE), and 17^{7-9,22,26-29,31,33,34,36,37,39,41,42} reported results for incident dementia. Diagnosis of dementia was based on DSM-III-R or DSM-IV ($n = 15$),^{7-9,22,24,26-29,31,33,34,36,37,39,41,42} Clinical Dementia Rating scale score ≥ 1 ($n = 1$),²³ or derived from standard diagnostic evaluation used in Finland ($n = 1$).²⁴ Ten studies^{21,23,25,27,29,31-34,42,43} provided results of neuropsychological testing. Due to variation in the timing of study visits, baseline age, and data on exposure to antihypertensive class, and cognitive test or dementia outcome, the number of studies combined in each meta-analysis varied.

Late-life >65 years, incident dementia

For those aged >65 years, we evaluated the effect of antihypertensive class compared to no antihypertensive treatment or placebo for incident dementia. After adjustment for age, sex, baseline SBP, and education, there was no association between CCB, ACE-I, BB, or ARB use and risk of developing dementia compared to those without treatment or with placebo and among studies with ≥ 5 -year or ≥ 1 -year follow-up (for ≥ 5 -year follow-up, see table 1 and figure 1, and for ≥ 1 -year follow-up, table e-2, doi.org/10.5061/dryad.t9n4n3p; and figure e-2, doi.org/10.5061/dryad.t9n4n3p; for full-size forest plots, see appendix e-B, doi.org/10.5061/dryad.t9n4n3p). Exposure to diuretics was associated with a statistically significant lower risk of incident dementia only in those with ≥ 1 -year follow-up (OR 0.83; 95% CI 0.72-0.96), but not statistically significant in those with ≥ 5 years of follow-up (OR 0.84; 95% CI 0.55-1.29). Unadjusted results showed a similar association (table e-3, doi.org/10.5061/dryad.t9n4n3p).


Table 1 Combined risk ratios for each antihypertensive class compared to no treatment or placebo for participants aged >65 years with ≥ 5 years follow-up

	Antihypertensive class				
	CCB	ACE-I	ARB	Diuretic	BB
Risk of developing dementia, pooled OR (95% CI)^a	0.92 (0.62-1.34)	1.14 (0.90-1.44)	0.95 (0.56-1.61)	0.84 (0.55-1.29)	1.17 (0.90-1.53)
No. of cohorts included	11	9	7	12	10
I² measure of heterogeneity, %	42	0	51.6	67.7	18.9
Publication bias, Egger test	$p = 0.5284$	$p = 0.7046$	$p = 0.2432$	$p = 0.1609$	$p = 0.2671$
Risk of developing cognitive decline as measured using the MMSE, pooled OR (95% CI)^a	0.87 (0.66-1.15)	0.92 (0.66-1.29)	0.96 (0.67-1.39)	0.81 (0.59-1.12)	0.97 (0.70-1.35)
No. of cohorts included	16	11	8	16	13
I² measure of heterogeneity, %	0	12.1	0	33.7	32.8
Publication bias, Egger test	$p = 0.6726$	$p = 0.9241$	$p = 0.17$	$p = 0.4881$	$p = 0.8862$

Abbreviations: ACE-I = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; BB = β -blockers; CCB = calcium channel blockers; CI = confidence interval; MMSE = Mini-Mental State Examination; OR = odds ratio.

^a Adjusted for sex, age, baseline systolic blood pressure, and education. Additional adjustment for ethnic group in the Einstein Aging Study.

Figure 1 Forest plots showing odds ratios for risk of developing dementia by exposure to each antihypertensive class compared to no treatment in participants aged over 65 years with ≥ 5 years follow-up



^aAdjusted for sex, age, baseline systolic blood pressure, and education. Additional adjustment for ethnic group in the Einstein Aging Study. ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BB = β -blocker; CCB = calcium channel blocker; CSHA = Canadian Study of Health and Ageing; GEM = Ginkgo Evaluation and Memory trial; HYVET = Hypertension in the Very Elderly Trial; MAAS = Maastricht Ageing Study; MYHAT = Monongahela Valley Independent Elders Survey; PreDIVA = Prevention of Dementia by Intensive Vascular Care; *Syst-Eur* = Systolic Hypertension in Europe.

An additional comparison between each antihypertensive class and those receiving any other antihypertensive treatment (cohort studies only) found no association between antihypertensive class, CCB, ACE-I, BB, ARB, or diuretic and risk of developing dementia in those with ≥ 5 -year or ≥ 1 -year follow-up (table 2 and table e-4, doi.org/10.5061/dryad.t9n4n3p).

Late life, >65 years, incident cognitive decline

We evaluated the effect of antihypertensive class compared to no antihypertensive treatment or placebo for incident cognitive decline. For incident cognitive decline using the RCI of the MMSE, results were not statistically significant for those with ≥ 5 -year or ≥ 1 -year follow-up for any drug

Table 2 Pooled odds ratios (ORs) for risk of dementia and cognitive decline comparing exposure to each antihypertensive drug class with exposure to other drug classes in participants with ≥ 5 years follow-up and aged >65 years

	Antihypertensive class				
	CCB	ACE-I	ARB	Diuretic	BB
Risk of developing dementia, pooled OR (95% CI)^a	0.76 (0.48–1.20)	1.01 (0.74–1.37)	0.93 (0.63–1.37)	0.75 (0.41–1.37)	1.13 (0.86–1.48)
No. of cohorts included	9	7	6	9	9
I² measure of heterogeneity, %	43.3	0	7.9	63.9	0
Publication bias, Egger test	$p = 0.5318$	$p = 0.0362$	$p = 0.8833$	$p = 0.399$	$p = 0.2906$
Risk of developing cognitive decline as measured using the MMSE, pooled OR (95% CI)^a	0.83 (0.61–1.12)	0.93 (0.67–1.28)	1.14 (0.76–1.72)	0.69 (0.51–0.92)	1.14 (0.87–1.48)
No. of cohorts included	12	9	6	12	11
I² measure of heterogeneity, %	0	0	0	0	0
Publication bias, Egger test	$p = 0.3596$	$p = 0.7415$	$p = 0.2331$	$p = 0.3748$	$p = 0.7175$

ACE-I = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; BB = β -blockers; CCB = calcium channel blockers; CI = confidence interval; MMSE = Mini-Mental State Examination.

^a Adjusted for sex, age, baseline systolic blood pressure, or presence of hypertension and education. Additional adjustment for ethnic group in the Einstein Aging Study.

classes (table 1 and table e-2, doi.org/10.5061/dryad.t9n4n3p; figure 2 and figure e-3, doi.org/10.5061/dryad.t9n4n3p; full-size forest plots in appendix e-B, doi.org/10.5061/dryad.t9n4n3p). Unadjusted results were similar (table e-3, doi.org/10.5061/dryad.t9n4n3p). Each antihypertensive class was also compared to those receiving any other antihypertensive treatment (cohort studies only). For incident cognitive decline measured using the RCI of the MMSE, results for CCB, ACE-I, ARB, and BB were similarly not statistically significant for ≥ 1 or ≥ 5 years follow-up. Exposure to diuretics was associated with a decreased risk of incident cognitive decline in those with ≥ 5 years of follow-up (OR 0.69; 95% CI 0.51–0.92) but not in those with ≥ 1 year of follow-up (OR 0.98; 95% CI 0.82–1.18) (table 2 and table e-4, doi.org/10.5061/dryad.t9n4n3p). Unadjusted results were similar (table e-5, doi.org/10.5061/dryad.t9n4n3p).

Data for further analyses per cognitive domain were available for a subset of cohorts and sufficient to allow meta-analyses for the cognitive domains of memory and attention but not for speed of processing or executive function. For memory, BB use was associated with an increased risk of decline in those with ≥ 1 -year follow-up pooled ratio (OR 1.53; 95% CI 1.04–2.27). There were no further statistically significant associations between AHM class and incident decline in memory or attention measures (table e-6, doi.org/10.5061/dryad.t9n4n3p).

Midlife ≤ 65 years

Fewer data were available in the ≤ 65 age group. No discernible pattern of results was evident for the differing antihypertensive classes (table e-7, doi.org/10.5061/dryad.t9n4n3p).

Heterogeneity and publication bias

Point estimates varied considerably in direction and magnitude per study (figures 1 and 2 and figures e-2 and e-3, doi.org/10.5061/dryad.t9n4n3p). Heterogeneity in the meta-analyses ranged from 0% to 67.7% (tables 1 and 2 and tables e-2 and e-3, doi.org/10.5061/dryad.t9n4n3p), but publication bias measured by Egger test was only observed for BB compared to the untreated population for dementia in those with ≥ 1 -year follow-up ($p = 0.0471$) and for ACE-I compared to those with other antihypertensive treatment for dementia in those with ≥ 5 years of follow-up ($p = 0.0362$). Overall, there were no consistent patterns for either dementia or cognitive decline outcomes.


Mortality and attrition by antihypertensive class

Additional analyses were performed to assess whether there was an association between baseline AHM class and risk of death or dropout. OR for the outcomes death and dropout (combined) for the different AHM classes adjusted for age, sex, education, and baseline SBP or, where this was unavailable, for presence of hypertension at baseline, were as follows: diuretics, OR 0.95 (95% CI 0.79–1.13); BB, OR 0.98 (95% CI 0.86–1.12); CCB, OR 0.93 (95% CI 0.76–1.13); ACE-I, OR 1.04 (95% CI 0.94–1.16); and ARB, OR 0.79 (95% CI 0.63–1.00). For some studies, data were available for either dropout or death but not both. Results did not change when the analyses were rerun excluding these studies.

Secondary analyses: Antihypertensive treatment compared to placebo or no treatment

Secondary analysis was carried out to examine the relationship between any AHM use (a minimum of 12 months

Figure 2 Forest plots showing odds ratios for risk of developing cognitive decline by exposure to each antihypertensive class compared to no treatment in participants aged over 65 years with ≥5 years follow-up



^aAdjusted for sex, age, baseline systolic blood pressure, and education. ^bCognitive decline classified using the reliable change index and a deterioration in the cognitive screening test, the Mini-Mental State Examination. ACE-I = angiotensin-converting enzyme inhibitor; ALSA = Australian Longitudinal Study of Aging; ARB = angiotensin receptor blocker; BB = β-blocker; CCB = calcium channel blocker; CFAS = Cognitive Function and Ageing Studies; CSHA = Canadian Study of Health and Ageing; GEM = Ginkgo Evaluation and Memory trial; HYVET = Hypertension in the Very Elderly Trial; MAAS = Maastricht Ageing Study; MAS = Sydney Memory and Ageing Study; MYHAT = Monongahela Valley Independent Elders Survey; PATH = Personality and Total Health study; PreDIVA = Prevention of Dementia by Intensive Vascular Care; Syst-Eur = Systolic Hypertension in Europe; TILDA = Irish Longitudinal Study on Ageing.

exposure) as compared to no treatment (cohorts) and to placebo (trials) for both incident dementia and cognitive decline.

In those aged >65 years, analysis of the cohort studies found no significant associations between AHM use and incident dementia or cognitive decline (MMSE RCI) in those with

≥1-year or ≥5-year follow-ups, adjusted for age, sex, education, and baseline SBP or presence of hypertension. Further analyses in a subset of 10 cohorts adjusting only for age, sex, and education to avoid overadjustment for BP did not change conclusions. In RCTs, there were no statistically significant associations between AHM use in RCT populations with ≥1-year follow-up and either incident dementia or cognitive decline (table e-8, doi.org/10.5061/dryad.t9n4n3p). However with ≥5 years of follow-up, AHM use was associated with a 35% lower risk of developing dementia in the fully adjusted pooled ratio (OR 0.65; 95% CI 0.51–0.82), but the association was not statistically significant with the risk of incident cognitive decline (OR 0.44; 95% CI 0.15–1.25).

In those aged ≤65 years, 2 cohort studies were available to compare antihypertensive treatment with no treatment or placebo and could be combined for the outcome of dementia in those with ≥5 years of follow-up (pooled OR 0.79; 95% CI, 0.43–1.48). Four cohorts were similarly pooled for the outcome of incident cognitive decline in those with ≥5 years of follow-up (pooled OR 1.00; 95% CI 0.60–1.67) and 2 cohorts for cognitive decline in those with ≥1 year of follow-up (pooled OR 1.15; 95% CI 0.81–1.64). There were 2 RCTs with data available for cognitive decline in those with ≥1 year of follow-up (pooled OR 0.91; 95% CI 0.57–6.42). There were no data to examine dementia outcomes in those with ≥1 year of follow-up.

Results for AHM treatment compared to no treatment were different for RCTs and cohort studies, and the RCTs reported the highest baseline SBP. It is possible that RCTs, despite the placebo effect, have had comparator untreated populations at higher risk than untreated populations in the cohort studies. Where data were available, the cohort studies in general reported only small to moderate differences between mean baseline BP in their treated and untreated populations. This suggests the possibility of some degree of successful BP control over time in the treated group, at least in some of the cohorts.

Sensitivity analyses

There were no clear patterns in findings or significant relationships by study type for those that were not trials of antihypertensives or when the OR of the participating study samples were plotted against decade of recruitment or percentage of female participants (appendix e-C, doi.org/10.5061/dryad.t9n4n3p). Furthermore, rerunning the treated and untreated comparison by sex in those >65 years showed no differences for men and women (table e-9, doi.org/10.5061/dryad.t9n4n3p).

Discussion

In this standardized comprehensive analysis examining the associations between AHM class and incident dementia or cognitive decline, we found no consistent pattern of evidence to support the benefit of one AHM class over another. In those aged >65 years, use of diuretics was associated with a reduced

risk, but this was not consistent across cognitive outcomes (dementia, cognitive decline), comparator group (no treatment or treatment with other antihypertensives), or length of follow-up (≥1 or ≥5 years). To be specific: (1) diuretic use compared to no AHM or placebo was not associated with a reduced risk of cognitive decline and was only associated with a reduced risk of dementia in those with ≥1 but not ≥5 years of follow-up; and (2) diuretic use compared to other AHM was not associated with a reduced risk of dementia and was only associated with a reduced risk of cognitive decline (MMSE) in those with ≥5 but not ≥1 year of follow-up. Use of BB compared to no AHM was associated with an increased risk of decline in memory in a subset of 7 cohorts with available data in those with ≥1 year of follow-up only and showed no relationship with incident dementia or general cognitive decline. Secondary analyses found AHM to be associated with a reduced risk of dementia and cognitive decline compared to placebo in hypertensive clinical trial populations with ≥5 years of follow-up. No association was observed in cohort studies.

Evidence in context

To our knowledge, this study is the first of its kind examining the effect of antihypertensive drug class on cognitive outcomes using reanalyzed individual data standardized across and assembled from individual studies. Similarly, it is the first, to our knowledge, that uses standardized measures of cognitive decline; looks separately at midlife and late life; requires a minimum exposure to antihypertensive treatment; and examines both short- and longer-term follow-up as recommended for the robust evaluation of incident dementia.¹⁰

The association between diuretics and reduced risk of cognitive decline or dementia is promising. However, given the variation in results from the individual studies and the lack of any consistently clear finding across cognitive outcomes, these results should be interpreted with caution. Furthermore, as one of the earlier classes of drug, diuretics may have been used more frequently as first-line treatment. As such, they may disproportionately represent those more recently diagnosed with hypertension or those with lower severity or chronicity of hypertension, which may have been associated with relatively lower risk of cognitive decline and dementia. The absence of a clear benefit of one antihypertensive class over another is congruent with the cardiovascular literature⁴⁷ and the mixed nature of the current evidence base. For example, the cognitive function literature has reported on different combinations of singular and multiple antihypertensive classes and found varying in favor of diuretics,¹² ARB,^{13,14} ACE-I,^{13,14} CCB,¹¹ and BB⁴⁸ without the evidence coalescing consistently in favor of one particular class.

Regarding AHM as a group, our meta-analyses that compared treated and untreated groups reported a significant result only in the RCT data of those with ≥5 years of follow-up. This is congruent with, but larger than, the reductions seen in the existing literature.⁹ One explanation for the lack of a finding in cohort studies could be the comparison of a higher-risk already-treated group with a lower-risk untreated

normotensive comparator group. That is not to imply that further reduction in BP would not result in a lowering of risk, as has recently been suggested in the Systolic Blood Pressure Intervention Trial–Memory and Cognition in Decreased Hypertension (SPRINT-MIND),⁴⁹ although of course close monitoring would be needed to avoid excessive lowering and potential harm. It is also possible that there are differences in the decision-making of participants when choosing to enter intervention studies compared with non-intervention-based cohort studies, leading to representation of different population groups, neither of which may be representative of the general population. There were, moreover, relatively few studies with data from the midlife age group or with domain-specific neuropsychological outcomes (which are arguably more robust than the MMSE). In addition, a recent study has suggested that genetic risk may influence the relationship between AHM, specifically ACE-I, and cognitive outcomes⁵⁰ and should therefore be taken into account, but these data were unavailable for our analyses.

Strengths and limitations

Prior systematic reviews, observational studies, and clinical trials reporting on antihypertensive class and cognition have risked bias due to inclusion of participants without requirement for any minimum follow-up or minimum exposure to a particular class, without separation of participants from mid and late-life, and often without standardization of cognitive decline. Unlike prior work, strengths of this study include (1) minimizing the risk of publication bias by deriving data from systematic literature searches and preexisting consortia; (2) combining data from a large number of participants across a wide geographical range of studies, maximizing the inclusion of relevant data; (3) standardization of exposure to antihypertensive classes (minimum exposure 1 year); (4) separation of data into exposure in mid and late-life age groups (>65, ≤65 years); (5) requirement of a minimum follow-up/lag period (≥1 and ≥5 years), i.e., excluding those who were followed for less than 12 months; (6) standardization of cognitive decline across varied time periods and taking account of variation within each sample; (7) standardization of statistical methods and available covariates; (8) use of both unadjusted and adjusted results; (9) comparison of each class against no treatment and against other antihypertensive treatment; and (10) a low level of heterogeneity in the analyses.

Limitations include a potential differential dropout or survivor bias in normotensive or controlled hypertensive participants; nevertheless, there was no association between baseline AHM class and subsequent dropout or death, suggesting no particular bias by class for inclusion in these longitudinal analyses. There was a lack of data available on individual drug or drug subclass and dose, reasons for prescription choice, and, as is common to all such observational studies and most clinical trials, an unavoidable overlap between classes, where participants are prescribed additional classes as needed to control their BP. However, if pleiotropic effects were present by class, they might be expected to be shown regardless. Furthermore,

there is no strong evidence as yet to suspect that any pleiotropic effect by class would manifest only in a subpopulation, and our results show no obvious pattern by age, sex, or decade of study recruitment. Further limitations include the inevitable use of a general cognitive screening instrument, the MMSE, which although allowing us comparability across studies is far from the sophisticated neuropsychological testing that would ideally be used to measure cognitive change. The classification or diagnosis of cognitive decline and dementia during a disease process with insidious onset and progression is also inevitably open to bias in any study and particularly where data are maximized in a combined study such as ours. Pragmatic use of the RCI and standardized dementia diagnoses for binary outcomes without taking time to event into account is the most robust option but may lose some of the subtleties available within individual cohorts.

Future perspectives

Outstanding questions remain and future research should investigate whether the results would differ had we been able to take fuller account of the changing relationships among BP, treatment, aging, and cognition using a life-course approach and had had access to further data from those younger than ≤65 years or examined those with existing cognitive impairment. It is also unclear whether there are selected drugs or subclasses that have particular protective or detrimental effects on cognition and the current studies were not equipped with sufficient detail to examine this. Future clinical trials could investigate this in detail using careful single drug comparisons and comprehensive neuropsychological testing. Furthermore, despite the positive results we found from the clinical trial samples we included, there has been no clinical trial designed primarily to test the effect of BP-lowering on cognitive function. This remains a crucial gap in the evidence base.

Our findings show some support for the message that lowering BP may lower dementia risk while also supporting clinical freedom in the selection of antihypertensive regimens to achieve BP goals.

Acknowledgment

R.P., S.Y., and K.J.A. conceived of and designed the research. Individual authors are responsible for the design and delivery of the constituent studies. R.P. and authors from the individual studies performed the analyses; data aggregation was by R.P.

Study funding

No targeted funding reported. The corresponding author is funded by the Australian National Health and Medical Research Council, National Institute for Dementia Research, and Dementia Centre for Research Collaboration (NHMRC NNIDR DCRC).

Disclosure

R. Peters and S. Yasar report no disclosures relevant to the manuscript. C. Anderson reports personal fees from

Amgen and Takeda outside the submitted work. S. Andrews reports no disclosures relevant to the manuscript. R. Antikainen reports personal fees from Amgen, Takeda, Novartis, Mundipharma, Finnish Societies of Cardiology, Palliative Care and Duodecim, and Finnish Society of Hypertension; other roles include board member of EUGMS, working group member of “The Future of Elderly People” of Ministry of Social Affairs and Health Finland, and working group member of “Drug Treatment of the Elderly People” of the Finnish Medicine Agency, outside the submitted work. H. Arima reports personal fees from Bayer, Daiichi Sankyo, and Takeda outside the submitted work. N. Beckett, J. Beer, A. Bertens, A. Booth, M. van Boxtel, C. Brayne, H. Brodaty, and M. Carlson report no disclosures relevant to the manuscript. J. Chalmers reports grants and personal fees from Servier International outside the submitted work. M. Corrada reports grants from the NIH during the conduct of the study. P.G. Kehoe reports grants from the National Institute of Health Research to undertake a phase II trial of an antihypertensive drug in mild to moderate Alzheimer’s disease where blood pressure may be normotensive or hypertensive. S. Dekosky reports personal fees from Amgen, Acumen, Biogen, and Cognition Therapeutics outside the submitted work. C. Derby, R. Dixon, and F. Forette report no disclosures relevant to the manuscript. M. Ganguli reports grants from the NIH and US DHHS during the conduct of the study, other support from the American Geriatric Society, personal fees from Indiana University and Biogen Inc., and nonfinancial support from Mount Sinai Medical Centre outside the submitted work. W. van Gool, A. Guaita, A. Hever, D. Hogan, C. Jagger, M. Katz, C. Kawas, P. Kehoe, S. Keinänen-Kiukaanniemi, R. Kenny, S. Köhler, S. Kunutsor, J. Laukkanen, C. Maxwell, G. McFall, T. van Middelaar, E. van Charante, T. Ng, and J. Peters report no disclosures relevant to the manuscript. I. Rawtaer reports grants from the Agency for Science Technology and Research, Biomedical Research Council, and National Research Council during the conduct of the study. E. Richard reports no disclosures relevant to the manuscript. K. Rockwood reports a role as Chief Scientific Officer for DGI Clinical, which holds contracts with Shire, Roche, Otsuka, Baxalta, Nutricia, Pfizer, and Luminosity and receives support from the Industrial Research Assistance Program of Industry Canada. L. Rydén and P. Sachdev report no disclosures relevant to the manuscript. I. Skoog reports personal fees from Takeda outside the submitted work. J. Skoog, J. Staessen, B. Stephan, S. Seibert, L. Thijs, S. Trompet, P. Tully, C. Tzourio, R. Vaccaro, E. Varamo, E. Walsh, J. Warwick, and K. Anstey report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Publication history

Received by *Neurology* November 26, 2018. Accepted in final form July 15, 2019.

Appendix 1 Authors

Author	Location	Role	Contributions
Ruth Peters, PhD	Neuroscience Research Australia and University of New South Wales, Australia	Author	Conceived and designed the study, finalized study design and delivery, contributed to the design or analysis for contributing study, carried out the meta-analyses, drafted the manuscript
Sevil Yasar, PhD	Johns Hopkins University	Author	Conceived and designed the study, finalized study design and delivery, contributed to the design or analysis for contributing study, commented on the manuscript
Craig S. Anderson, PhD	The George Institute for Global Health, Faculty of Medicine, UNSW, Australia	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Shea Andrews, PhD	Icahn School of Medicine at Mount Sinai	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Riitta Antikainen, PhD	University of Oulu, Finland	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Hisatomi Arima, PhD	Department of Preventive Medicine and Public Health, Fukuoka University, Japan	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Nigel Beckett, MD	Guys and St Thomas' NHS Foundation Trust, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Joanne C. Beer, PhD	University of Pittsburgh	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Anne Suzanne Bertens, MD	Leiden University Medical Centre, the Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Andrew Booth, PhD	University of Sheffield, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Martin van Boxtel, PhD	Maastricht University Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript

Appendix 1 (continued)

Author	Location	Role	Contributions
Carol Brayne, MD	University of Cambridge, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Henry Brodaty, DSc	University of New South Wales, Australia	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Michelle C. Carlson, PhD	Johns Hopkins University	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
John Chalmers, PhD	The George Institute for Global Health, Faculty of Medicine, UNSW, Australia	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Maria M. Corrada, ScD	University of California	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Steven DeKosky, MD	University of Florida	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Carol Derby, PhD	Albert Einstein College of Medicine	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Roger A. Dixon, PhD	University of Alberta, Canada	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Françoise Forette, MD	International Longevity Centre, France	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Mary Ganguli, MD	University of Pittsburgh	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Willem A. van Gool, PhD	University of Amsterdam, the Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Antonio Guaita, MD	Golgi Cenci Foundation, Italy	Author	Contributed to the design or analysis for contributing study, commented on the manuscript

Appendix 1 (continued)

Author	Location	Role	Contributions
Ann M. Hever, PhD	Trinity College, Dublin, Ireland	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
David B. Hogan, MD	University of Calgary, Canada	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Carol Jagger, PhD	University of Newcastle, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Mindy Katz, MPH	Albert Einstein College of Medicine	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Claudia Kawas, MD	University of California	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Patrick G. Kehoe, PhD	University of Bristol, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Sirkka Keinanen-Kiukaanniemi, PhD	University of Oulu, Finland	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Rose Ann Kenny, MD	Trinity College, Dublin, Ireland	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Sebastian Köhler, PhD	Maastricht University, the Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Setor Kunutsor, PhD	University of Bristol, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Jari Laukkanen, PhD	University of Eastern Finland	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Colleen Maxwell, PhD	University of Waterloo, Canada	Author	Contributed to the design or analysis for contributing study, commented on the manuscript

Continued

Appendix 1 (continued)

Author	Location	Role	Contributions
G. Peggy McFall, PhD	University of Alberta, Canada	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Tessa van Middelaar, MD	Department of Neurology, Academic Medical Center, Amsterdam, and Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Eric P. Moll van Charante, PhD	University of Amsterdam, the Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Tze-Pin Ng, MD	National University of Singapore	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Jean Peters, PhD	University of Sheffield, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Iris Rawtaer, MMed	National University of Singapore	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Edo Richard, PhD	Department of Neurology, Academic Medical Center, Amsterdam, and Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Kenneth Rockwood, MD	Dalhousie University, Canada	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Lina Rydén, MD	University of Gothenburg, Sweden	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Perminder S. Sachdev, MD	University of New South Wales, Australia	Author	Contributed to the design or analysis for contributing study, commented on the manuscript

Appendix 1 (continued)

Author	Location	Role	Contributions
Ingmar Skoog, PhD	University of Gothenburg, Sweden	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Johan Skoog, MSc	University of Gothenburg, Sweden	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Jan A. Staessen, PhD	University of Leuven, Belgium	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Blossom C.M. Stephan, PhD	University of Newcastle, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Sylvain Sebert, PhD	University of Oulu, Finland	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Lutgarde Thijs, PhD	University of Leuven, Belgium	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Stella Trompet, PhD	Leiden University Medical Center, the Netherlands	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Phillip J. Tully, PhD	University of Bordeaux, France; University of Adelaide, Australia	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Christophe Tzourio, PhD	University of Bordeaux, France	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Roberta Vaccaro, MSc	Golgi Cenci Foundation, Italy	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Eeva Vaaramo, MSc	University of Oulu, Finland	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Erin Walsh, PhD	Australian National University	Author	Contributed to the design or analysis for contributing study, commented on the manuscript

Appendix 1 (continued)

Author	Location	Role	Contributions
Jane Warwick, PhD	University of Warwick, UK	Author	Contributed to the design or analysis for contributing study, commented on the manuscript
Kaarin J. Anstey, PhD	Neuroscience Research Australia and University of New South Wales, Australia	Author	Finalized study design and delivery, contributed to the design or analysis for contributing study, commented on the manuscript

Appendix 2 Participating studies

Participating studies	Participating studies details
The Three-City Study	The Three-City Study is conducted under a partnership agreement among the Institut National de la Santé et de la Recherche Médicale (INSERM), the Institut de Santé Publique et Développement de la Recherche Segalen 2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The Three-City Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l'Éducation Nationale, Institut de la Longévité, Regional Governments of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research-INSERM Programme "Cohortes et collections de données biologiques." This work was carried out with the financial support of the "ANR—Agence Nationale de la Recherche—The French National Research Agency" under the "Programme National de Recherche en Alimentation et Nutrition Humaine," project "COGINUT ANR-06-PNRA-005." Three-City Study supports are listed on the study website (www.three-city-study.com). The authors thank the study team and participants of the Three-City Study.
90+ Study	Supported by US funding awards R01 AG21055 and R01 AG042444. The authors thank the study team and participants of the 90+ Study.
Australian Longitudinal Study of Aging (ALSA)	The authors thank the study team and participants of the ALSA and Shaun Lehmann for help with drug coding.
Canadian Study of Health and Ageing (CSHA)	The CSHA was funded by the Seniors' Independence Research Program through the National Health Research and Development Program, project 6606-3954-MC (S). Additional funding was provided by Pfizer Canada Incorporated through the Medical Research Council/Pharmaceutical Manufacturers Association of Canada Health Activity Program, National Health Research and Development Program project 6603-1417-302(R). The study was coordinated through the University of Ottawa and Health Canada's Division of Aging and Seniors. The authors thank the study team and participants of the CSHA.

Appendix 2 (continued)

Participating studies	Participating studies details
Cognitive Function and Ageing Studies (CFAS I, CFAS II)	CFAS I: The Medical Research Council (MRC) CFAS is supported by major awards from the MRC, research grant G9901400, and the UK Department of Health. The authors thank the local GPs and their staff for support and assistance, the interviewers, and the residents of East Cambridgeshire, Liverpool, Ynys Mon, Dwyfor, Newcastle upon Tyne, Nottingham, and Oxford for their continuing participation in the study. CFAS II is supported by the MRC, research grant G0601022, the National Institute for Health Research (NIHR) comprehensive clinical research networks (CLRN) in West Anglia and Trent, and the Dementias and Neurodegenerative Disease Research Network (DeNDRoN) in Newcastle. CFAS is a member of the collaboration for leadership in applied health research and care for the east of England (CLAHRC EoE), the Cambridge Biomedical Research Centre infrastructures, Nottingham City and Nottinghamshire County NHS primary care trusts, and the UK NIHR Biomedical Research Centre for Ageing and Age-related Disease award to the Newcastle-Upon-Tyne hospital foundation trust. The authors thank the participants, their families, the general practitioners and their staff, and the primary care trusts for their cooperation and support, and the CFAS II fieldwork interviewers at Cambridge, Nottingham, and Newcastle.
Einstein Aging Study (EAS)	The EAS is supported by NIH/NIA 2 P01 AG 03949. The authors thank the study team and participants of the EAS.
Ginkgo Evaluation and Memory Trial (GEM)	The authors thank the study team and participants of the GEM.
Göteborg H70 Birth Cohort Studies	The authors thank the study team and participants of the 1922 and 1930 cohorts. Funded by the Swedish Research Council (2015-02830, 2013-8717), Swedish Research Council for Health, Working Life and Welfare (2008-1229, 2012-1138, 2010-0870, 2013-2300, 2013-2496, 2013-0475, 2006-1506), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Hjärnfonden, Sahlgrenska University Hospital (ALF), The Alzheimer's Association Stephanie B. Overstreet Scholars (IIRG-00-2159), Eivind och Elsa K:son Sylvans stiftelse, and Swedish Alzheimer Foundation.
Hypertension in the Very Elderly Trial	See full acknowledgements and funding sources as cited in reference 51.
Invecchiamento Cerebrale in Abbiategrosso study (InveCe.Ab)	The authors thank the study team and participants of the InveCe.Ab study and "Federazione Alzheimer Italia," Milan, for partially funding the study.
Irish Longitudinal Study on Ageing (TILDA)	The authors thank the study team and participants of TILDA. Researchers interested in using TILDA data may access the data for free from the following sites: Irish Social Science Data Archive (ISSDA) at University College Dublin (ucd.ie/issda/data/tilda/); and Interuniversity Consortium for Political and Social Research (ICPSR) at the University of Michigan (icpsr.umich.edu/icpsrweb/ICPSR/studies/34315). TILDA is supported by the Irish Government, The Atlantic Philanthropies, and Irish Life plc.

Continued

Appendix 2 (continued)

Participating studies	Participating studies details
Kuopio Ischaemic Heart Disease Risk Factor Study	The authors thank the staff of the Kuopio Research Institute of Exercise Medicine and the Research Institute of Public Health and University of Eastern Finland, Kuopio, for the data collection in the study.
Leiden 85+ Study	The Leiden 85+ Study is partly funded by the Dutch Ministry of Health, Welfare, and Sports. The authors thank Anton J.M. de Craen (deceased) for his work for the Leiden 85+ Study.
Maastricht Ageing Study (MAAS)	The authors thank the study team and participants of the MAAS.
Monongahela-Youghiogheny Healthy Aging Team (MYHAT)	MYHAT was funded by research grant R01 AG023651 from the National Institute on Aging, US Department of Health and Human Services. The authors thank Dr. Tianxiu Wang for performing the analyses and the study team and participants of MYHAT.
Newcastle 85+ Study	The Newcastle 85+ Study was funded by the Medical Research Council, Biotechnology and Biological Sciences Research Council, the Dunhill Medical Trust, Newcastle University, and the North of England Commissioning Support Unit (formerly NHS North of Tyne). The research was also supported by the National Institute for Health Research, Newcastle Biomedical Research Centre, based at Newcastle upon Tyne Hospitals. The authors thank the North of England Commissioning Support Unit and the local general practitioners and their staff for operational support; the research, management, and clerical team; and the study participants and their families and carers.
Oulu Cohort Ageing Study	The authors thank the participants of the Oulu Cohort Ageing Study.
Personality and Total Health Study (PATH)	The PATH Through Life Project is being undertaken by the Centre for Research on Ageing, Health and Well-being at the Australian National University. The authors thank the study participants, PATH interviewers, and PATH chief investigators. The PATH Through Life Study was funded by National Health and Medical Research Council grants: PATH wave 1: NHMRC program grants 229936 and 179839; PATH wave 2: NHMRC program grant 179805; PATH wave 3: NHMRC project grant 418039; PATH wave 4: NHMRC project grant 1002160.
Prevention of Dementia by Intensive Vascular Care (PreDIVA)	The PreDIVA trial was supported by the Dutch Ministry of Health, Welfare and Sports (50-50110-98-020), the Innovatiefonds Zorgverzekeraars (innovation fund of collaborative health insurances, 05-234), and ZonMw (The Netherlands Organisation for Health Research and Development, 62000015). The authors thank participants of the preDIVA study; practice nurses who delivered the intervention; general practitioners involved in care for the participants; Suzanne A. Ligthart, MD, PhD, Lisa S.M. Eurelings, MD, PhD, Jan W. van Dalen, MSc, Carin E. Miedema, and Marieke P. Hoevenaar-Blom, PhD; and Fay Spyropoulou for help with Anatomical Therapeutic Chemical coding.
The Perindopril Protection against Recurrent Stroke Study (PROGRESS)	The authors thank the study team and participants of PROGRESS.

Appendix 2 (continued)

Participating studies	Participating studies details
Singapore Longitudinal Ageing Study (SLAS)	The study was supported by research grants from the Agency for Science Technology and Research (A*STAR) Biomedical Research Council (BMRC) (grants 03/1/21/17/214, 08/1/21/19/567) and the National Medical Research Council (grant NMRC/1108/2007). The authors thank the study team, in particular Evie Goh, Gao Qi, and Soh Chang Yuan, and participants of SLAS. The authors thank the following voluntary welfare organizations for their support: Geylang East Home for the Aged, Presbyterian Community Services, St Luke's Eldercare Services, Thyee Hua Kwan Moral Society (Moral Neighbourhood Links), Yuhua Neighbourhood Link, Henderson Senior Citizens' Home, NTUC Eldercare Co-op Ltd., Thong Kheng Seniors Activity Centre (Queenstown Centre), and Redhill Moral Seniors Activity Centre.
Sydney Memory and Ageing Study (MAS)	The authors thank the study team and participants of MAS.
Systolic Hypertension in Europe Trial (SYST-EUR)	See full acknowledgements and funding sources as cited in reference 7.
Systolic Hypertension in the Elderly Project (SHEP)	This article was prepared using SHEP Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of SHEP or NHLBI.
Victoria Longitudinal Study	The authors thank Stuart MacDonald and the VLS team and participants for their contributions and acknowledge funding from the NIH (National Institute on Aging): R01 AG008235 to R.A. Dixon (PI).

References

1. Alzheimers Disease International. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost, and Trends. London: Alzheimers Disease International; 2015.
2. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology* 2007;69:2197–2204.
3. Yasar S, Schuchman M, Peters J, Anstey KJ, Carlson MC, Peters R. Relationship between antihypertensive medications and cognitive impairment: part I: review of human studies and clinical trials. *Curr Hypertens Rep* 2016;18:1522–6417.
4. Peters R, Schuchman M, Peters J, Carlson MC, Yasar S. Relationship between antihypertensive medications and cognitive impairment: part II: review of physiology and animal studies. *Curr Hypertens Rep* 2016;18:1522–6417.
5. Elias M, Wolf P, D'Agostino R, Cobb J, White L. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study. *Am J Epidemiol* 1993;138:353–364.
6. Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer's disease: progress towards disease prevention and treatment? *J Alzheimer Dis* 2018;62:1443–1466.
7. Forette F, Seux M, Staessen J, et al; Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment. *Arch Intern Med* 2002;162:2046–2052.
8. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. *Arch Intern Med* 2003;163:1069–1075.
9. Peters R, Beckett N, Forette F, et al; for the HYVET Investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial Cognitive Function Assessment (HYVET-COG), a double-blind placebo controlled trial. *Lancet Neurol* 2008;7:683–689.
10. Skoog I. Antihypertensive treatment and dementia prevention. *Lancet Neurol* 2008;7:664–665.
11. Peters R, Booth A, Peters J. A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. *J Hypertens* 2014;32:1945–1958.
12. Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies. *J Hypertens* 2016;34:1027–1035.

13. Shah K, Qureshi S, Johnson M, Parikh N, Schulz P, Kunik M. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. *Am J Geriatr Pharmacother* 2009;7:v250–261.
14. Levi N, Macquin-Mavier I, Tropeano A, Bachoud-Levi A, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. *J Hypertens* 2013;31:1073–1082.
15. Stein J, Luppá M, Brähler E, König HH, Riedel-Heller SG. The assessment of changes in cognitive functioning: reliable change indices for neuropsychological instruments in the elderly: a systematic review. *Dement Geriatr Cogn Disord* 2010;29:275–286.
16. Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Alzheimer Dement* 2005;1:55–66.
17. Tzourio C, Dufouil C, Ducimetière P, Alperovitch A; for the EVA study group. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. *Neurology* 1999;53:1948–1952.
18. Prince M, Ferri C, Acosta D, et al. The protocols for the 10/66 dementia research group population-based research programme. *BMC Public Health* 2007;7:165.
19. Houx PJ, Shepherd J, Blaw G, et al. Testing cognitive function in elderly populations: the PROSPER study. *J Neurol Neurosurg Psychiatry* 2002;73:385–389.
20. Lim S, Yoon JW, Choi SH, et al. Combined impact of adiponectin and retinol-binding protein 4 on metabolic syndrome in elderly people: the Korean Longitudinal Study on Health and Aging. *Obesity* 2010;18:826–832.
21. Dixon R, Frias C. The Victoria Longitudinal Study: from characterizing cognitive aging to illustrating changes in memory compensation aging. *Neuropsychol Cogn* 2004;11:346–376.
22. Yasar S, Xia J, Yao W, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Antihypertensive drugs decrease risk of Alzheimer's disease: Ginkgo Evaluation on Memory Study. *Neurol* 2013;81:896–903.
23. Ganguli M, Snitz B, Vander Bilt J, Chang C. How much do depressive symptoms affect cognition at the population level? The Monongahela-Youghioheny Healthy Aging Team (MYHAT) Study. *Int J Geriatr Psychiatry* 2009;24:1277–1284.
24. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. *Ann Clin Res* 1988;20:46–50.
25. Anstey K, Christensen H, Butterworth P, et al. Cohort profile: the PATH through life project. *Int J Epidemiol* 2012;41:951–960.
26. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: the 90+ study. *Ann Neurol* 2010;67:114–121.
27. Guaita A, Colombo M, Vaccaro R, et al. Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study. *BMC Geriatr* 2013;13:98.
28. Van Bostel M, Buntinx F, Houx P, Metsemakers J, Knottnerus J, Jolles J. The relation between morbidity and cognitive performance in a normal aging population. *J Gerontol* 1998;53A:M146–M154.
29. Maxwell C, Hogan D, Eby E. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. *CMAJ* 1999;161:501–506.
30. Luszcz M, Giles L, Anstey KJ, Browne-Yung K, Walker R, Windsor T. Cohort profile: the Australian Longitudinal Study of Ageing (ALSA). *Int J Epidemiol* 2016;45:1054–1063.
31. The 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. *Neuroepidemiol* 2003;22:316–325.
32. Saukkonen T, Jokelainen J, Timonen M, et al. Prevalence of metabolic syndrome components among the elderly using three different definitions: a cohort study in Finland. *Scand J Prim Care* 2012;30:29–34.
33. Joas E, Guo X, Kern S, Östling S, Skoog I. Sex differences in time trends of blood pressure among Swedish septuagenarians examined three decades apart: a longitudinal population study. *J Hypertens* 2017;35:1424–1431.
34. Skoog I, Waern M, Duberstein P, et al. A 9-year prospective population-based study on the association between the APOE ε4 allele and late-life depression in Sweden. *Biol Psychiatry* 2015;78:730–736.
35. Peters R, Collerton J, Granic A, Davies K, Kirkwood T, Jagger C. Antihypertensive drug use and risk of cognitive decline in the very old: an observational study: the Newcastle 85+ Study. *J Hypertens* 2015;33:2156–2164.
36. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. *Lancet* 2016;388:797–805.
37. Joas E, Bäckman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. *Hypertens* 2012;59:796–801.
38. Trompet S, Westendorp R, Kamper A, Craen A. Use of calcium antagonists and cognitive decline in old age the Leiden 85-plus study. *Neurobiol Aging* 2008;29:306–308.
39. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension. *J Am Med Assoc* 1991;265:3255–3264.
40. MRC CFAS. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. *Psychol Med* 1998;28:319–335.
41. Matthews FE, Stephan BCM, Robinson L, et al; Cognitive Function and Ageing Studies (CFAS) Collaboration. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. *Nat Commun* 2016;7:11398.
42. Derby CA, Katz MJ, Lipton RB, Hall CB. Trends in dementia incidence in a birth cohort analysis of the Einstein Aging Study. *JAMA Neurol* 2017;74:1345–1351.
43. Sachdev PS, Brodaty H, Reppermund S, et al; Memory and Ageing Study Team. The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. *Int Psychogeriatr* 2010;22:1248–1264.
44. Kearney PM, Cronin H, O'Regan C, et al. Cohort profile: the Irish Longitudinal Study on Ageing. *Int J Epidemiol* 2011;40:877–884.
45. Kenny R, Whelan B, Cronin H, et al. The Design of the Irish Longitudinal Study on Ageing. Dublin: Trinity College Dublin; 2010. Available at: ucd.ie/t4cms/0053-00_TILDA_Design_Report.pdf. Accessed January 29, 2018.
46. Ng TP, Feng L, Nyunt MSZ, et al. Metabolic syndrome and the risk of mild cognitive impairment and progression to dementia follow-up of the Singapore Longitudinal Ageing Study cohort. *JAMA Neurol* 2016;73:456–463.
47. Czernichow S, Zanchetti A, Turnbull F, et al; on behalf of the Blood Pressure Lowering Treatment Trialists Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomised trials. *J Hypertens* 2011;29:4–16.
48. Gelber R, Ross G, Petrovitch H, Masaki K, Launer L, White L. Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia Aging Study. *Neurol* 2013;81:1–8.
49. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015;373:2103–2116.
50. de Oliveira FF, Chen ES, Smith MC, Bertolucci PHF. Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer's disease dementia. *Curr Alzheimer Res* 2018;15:386–398.
51. Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomized controlled trial. *BMJ* 2012;344:d7541.

Neurology®

Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis

Ruth Peters, Sevil Yasar, Craig S. Anderson, et al.

Neurology 2020;94:e267-e281 Published Online before print December 11, 2019

DOI 10.1212/WNL.00000000000008732

This information is current as of December 11, 2019

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/94/3/e267.full
References	This article cites 49 articles, 6 of which you can access for free at: http://n.neurology.org/content/94/3/e267.full#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/94/3/e267.full##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Cognitive Disorders/Dementia http://n.neurology.org/cgi/collection/all_cognitive_disorders_dementia
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

